Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 1
2013 6
2014 5
2015 10
2016 14
2017 18
2018 15
2019 20
2020 25
2021 32
2022 11
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 33517260

148 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors in Prostate Cancer.
Grewal K, Grewal K, Tabbara IA. Grewal K, et al. Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807. Anticancer Res. 2021. PMID: 33517260 Review.
PARP inhibitors for ovarian cancer.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2017 Dec 4;59(1535):200-202. Med Lett Drugs Ther. 2017. PMID: 29186085 No abstract available.
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Update on PARP Inhibitors in Breast Cancer.
Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Zimmer AS, et al. Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Curr Treat Options Oncol. 2018. PMID: 29644491 Free PMC article. Review.
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Rafii S, et al. Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005. Oncotarget. 2017. PMID: 28454085 Free PMC article.
148 results